DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: CIPRO

Summary for Tradename: CIPRO

Patents:8
Applicants:40
NDAs:55
Suppliers: see list2
drug
patent expirations by year for
 CIPRO

Pharmacology for Tradename: CIPRO

Ingredient-typeQuinolones
Drug ClassQuinolone Antimicrobial

Clinical Trials for: CIPRO

Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro Compared to Twice-Daily Dosing of Ciloxan Ear Drops in Patients With Acute External Otitis
Status: Completed Condition: Otitis Externa; Otorhinolaryngologic Diseases; Ear Diseases; Otitis

Safety and Efficacy Study of Foam Otic Cipro Compared to a Standard Solution ( Ciloxan - Alcon Labs ) to Treat Acute Otitis Externa
Status: Completed Condition: Otitis Externa; Otorhinolaryngologic Diseases; Ear Diseases; Otitis

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis
Status: Completed Condition: Cystic Fibrosis

Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens
Status: Completed Condition: Urinary Tract Infections

Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis
Status: Completed Condition: Bronchiectasis

A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension
Status: Not yet recruiting Condition: Otitis Externa

Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections
Status: Completed Condition: Urinary Tract Infection

Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed Condition: Disease, Pulmonary

Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder
Status: Completed Condition: Infection; Pulmonary Disease, Chronic Obstructive

A Phase IV Study of Cipro XR in Uncomplicated UTI
Status: Completed Condition: Urinary Tract Infections

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acs Dobfar Info Sa
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
ciprofloxacin
INJECTABLE;INJECTION078252Mar 18, 2008RXNo<disabled><disabled>
Akorn Inc
CIPROFLOXACIN HYDROCHLORIDE
ciprofloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC076555Dec 11, 2008RXNo<disabled><disabled>
Alcon Pharms Ltd
CIPRO HC
ciprofloxacin hydrochloride; hydrocortisone
SUSPENSION/DROPS;OTIC020805Feb 10, 1998RXYes5,843,930<disabled><disabled>
Alcon Pharms Ltd
CIPRO HC
ciprofloxacin hydrochloride; hydrocortisone
SUSPENSION/DROPS;OTIC020805Feb 10, 1998RXYes5,965,549<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CIPRO

Drugname Dosage Strength RLD Submissiondate
ciprofloxacinOral Suspension250 mg/5 mL and 500 mg/ 5 mLCipro10/16/2009

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc